Antibodies to neutrophil cytoplasma in patients with ulcerative colitis and their first‐degree relatives in Thailand

Osangthamnont, Charkaphan; Manatsathit, Sathaporn; Pongprasopchai, Supot; Viriyataveekul, Ronnachai; Chaihirunkarn, Supaporn; Leelakusolvong, Somchai; Boonyapisit, Sasiprapa

doi:10.1046/j.1440-1746.2001.02546.x

Cited by 7 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the observed prevalence fits within the previously reported range, it was quite low compared to that observed in Western countries [10,17,21] and is closer to the results of studies initiated in Asian countries [20,22]. Differences in clinical patterns of UC between races or ethnic groups may help us to understand the etiology or pathogenesis of the disease.…”

Section: Discussionsupporting

confidence: 86%

“…Therefore, we speculated that the phenotype and characteristics of UC, including pANCA status, might differ between Western and Asian populations. However, there are little data concerning the prevalence of pANCA and its clinical significance in Asia [20], and the available data are limited by small sample sizes. Based on the above, it might be valuable to investigate the prevalence and clinical significance of pANCA in a large series of Korean patients with UC that have very different environmental and genetic backgrounds from Western populations.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Prevalence and Clinical Significance of Perinuclear Anti-neutrophil Cytoplasmic Antibody in Korean Patients with Ulcerative Colitis

et al. 2009

View full text Add to dashboard Cite

Perinuclear anti-neutrophil cytoplasmic antibody (pANCA) is a serological marker associated with various immune-mediated diseases whose clinical significance and possible diagnostic roles in ulcerative colitis (UC) are still unclear. We aimed to evaluate the prevalence of pANCA expression and its association with clinical findings and disease course in Korean patients with UC. This study included 484 patients with UC who were diagnosed and treated between 1990 and 2006 at Severance Hospital, Yonsei University, Seoul, Korea, and were followed for at least 1 year. Clinical findings at diagnosis, disease extent, treatment modalities used, and cumulative relapse rates were analyzed and compared to pANCA expression. Of the 484 patients, 405 (83.7%) were evaluated for pANCA and were eligible for analysis. The overall pANCA prevalence was 22.1%, with a female preponderance (male, 21.5%; female, 31.6%; P < 0.05). Proctitis was more common in pANCA-negative patients (pANCA-negative, 37.6%; pANCA-positive, 25.2%, P < 0.05). UC activity index and cumulative relapse rates were higher in pANCA-positive patients. However, there were no significant differences in the cumulative probability of steroid and immunosuppressant use and operation rate between the two groups. The prevalence of pANCA expression in Korean patients with UC was relatively low compared to that in Western countries. Although UC patients with pANCA expression had more severe clinical findings at diagnosis and higher cumulative relapse rates in our study, further prospective studies are warranted to clarify whether pANCA positivity influences the initial clinical presentation or disease aggressiveness.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

The Prevalence and Clinical Significance of Perinuclear Anti-neutrophil Cytoplasmic Antibody in Korean Patients with Ulcerative Colitis

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The prevalence of pANCA in Japanese,148 Korean,149 Thai,150 and Romanian151 patients with UC is lower compared with Caucasians, but comparable to Caucasian data in Mexico,152 Estonia,153 and a different Korean cohort 142. pANCA was found more frequently in UC patients with more extensive disease in China147 and Korea,149 with relapse rates higher when pANCA was present in the Korean cohort 149…”

Section: Ethnic Differences In Serological Antibodiessupporting

confidence: 52%

Serological Antibodies in Inflammatory Bowel Disease: A Systematic Review

Prideaux

Cruz

et al. 2012

Inflammatory Bowel Diseases

166

145

View full text Add to dashboard Cite

The diagnosis of inflammatory bowel disease (IBD) is traditionally based on a combination of clinical, endoscopic, histological, and radiological criteria. However, further testing is needed in cases of diagnostic uncertainty and in predicting disease course. This systematic review focuses on the potential for 10 serological antibodies to fill these roles: pANCA, ASCA, anti-OmpC, anti-CBir1, anti-I2, ALCA, ACCA, AMCA, anti-L, and anti-C. We discuss their prevalence in IBD and health; their role in disease diagnosis and risk stratification; their stability over time; their presence in unaffected relatives; their association with genetic variants; and differences across ethnic groups. Serological antibodies have some role in primary diagnosis and in differentiating between Crohn's disease and ulcerative colitis. In indeterminate colitis, preoperative measurement of serological antibodies can help to predict the likelihood of complications among patients undergoing pouch surgery. The combined presence and magnitude of a large panel of antibodies appear to be of value in predicting disease progression. There is currently insufficient evidence to recommend the use of antibody testing to predict responses to treatment or surgery in patients with IBD.

show abstract

“…Serological markers perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) have been extensively studied in the Caucasian IBD population 45 but less data exists for Asian IBD patients. [46][47][48][49][50][51][52][53][54][55] Although pANCA and ASCA are more specific for UC and CD, respectively, their usefulness is limited by their low sensitivity and not required for the diagnosis of UC in clinical practice. In a meta-analysis, pANCA positivity alone has a 55.3% sensitivity and 88.5% specificity for UC.…”

Section: Level Of Agreement: A-65% B-23% C-12% D-0% E-0% Quality mentioning

confidence: 99%

The Asia‐Pacific consensus on ulcerative colitis

Ooi

Fock

Makharia

et al. 2010

J of Gastro and Hepatol

Self Cite

139

101

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is increasing in many parts of the Asia-Pacific region. There is a need to improve the awareness of IBD and develop diagnostic and management recommendations relevant to the region. This evidence-based consensus focuses on the definition, epidemiology and management of ulcerative colitis (UC) in Asia.A multi-disciplinary group developed the consensus statements, reviewed the relevant literature, and voted on them anonymously using the Delphi method. The finalized statements were reviewed to determine the level of consensus, evidence quality and strength of recommendation.Infectious colitis must be excluded prior to diagnosing UC. Typical histology and macroscopic extent of the disease seen in the West is found in the Asia-Pacific region. Ulcerative colitis is increasing in many parts of Asia with gender distribution and age of diagnosis similar to the West. Extra-intestinal manifestations including primary sclerosing cholangitis are rarer than in the West. Clinical stratification of disease severity guides management. In Japan, leukocytapheresis is a treatment option. Access to biologic agents remains limited due to high cost and concern over opportunistic infections. The high endemic rates of hepatitis B virus infection require stringent screening before initiating immune-suppressive agents. Vaccination and prophylactic therapies should be initiated on a case-by-case basis and in accordance with local practice. Colorectal cancer complicates chronic colitis.A recent increase in UC is reported in the Asia-Pacific region. These consensus statements aim to improve the recognition of UC and assist clinicians in its management with particular relevance to the region.

show abstract

Antibodies to neutrophil cytoplasma in patients with ulcerative colitis and their first‐degree relatives in Thailand

Cited by 7 publications

References 38 publications

The Prevalence and Clinical Significance of Perinuclear Anti-neutrophil Cytoplasmic Antibody in Korean Patients with Ulcerative Colitis

The Prevalence and Clinical Significance of Perinuclear Anti-neutrophil Cytoplasmic Antibody in Korean Patients with Ulcerative Colitis

Serological Antibodies in Inflammatory Bowel Disease: A Systematic Review

The Asia‐Pacific consensus on ulcerative colitis

Contact Info

Product

Resources

About